CANTO skin: Evaluation of skin toxicity risk factors in patients treated for breast cancer.
CANTO
breast cancer
risk factor
skin toxicity
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 11 2023
15 11 2023
Historique:
received:
18
06
2023
accepted:
21
06
2023
medline:
19
9
2023
pubmed:
13
8
2023
entrez:
12
8
2023
Statut:
ppublish
Résumé
Skin reaction is a common toxicity during oncology management, especially followed during the radiotherapy. Its assessment and understanding of the factors influencing its occurrence, is a major issue in the management of patients treated for an early breast cancer (BC). We evaluated 8561 patients during their overall management for a BC. We focus on specific skin toxicities: erythema, fibrosis, telangiectasia and changes of skin colour. These toxicities were assessed at the baseline defined as 0-3-6 (M0), 12 (M12), 36 (M36) and 60 (M60) months. The prevalence of toxicities of interest varied over time, so at M0, 30.4% of patients had erythema while 17.7% of patients had fibrosis. At M60, the prevalence of erythema was 2%, while fibrosis remained stable at about 19%. After adjustments, at M0, there was a significant association between the onset of cutaneous erythema and obesity, the presence of axillary dissection, the type of surgery and the tumour phenotype RH+/HER2+. Concerning fibrosis, a significant association was found, at M12, with the age of the patient, obesity, Charlson score and type of surgery. Concerning the modification of skin colour at M12, we find a link between the age of the patient, obesity, tobacco consumption and alcohol consumption. The prevention of this toxicity is a major issue for the quality of life. Our results allow us to understand the risk of developing skin toxicity in a patient, depending on her intrinsic, tumour or therapeutic characteristics and to implement adapted means of prevention and monitoring.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1797-1808Informations de copyright
© 2023 UICC.
Références
Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006. J Am Acad Dermatol. 2006;54(1):28-46.
Savarese DM. Common Terminology Criteria for Adverse Events. Waltham: UpToDate; 2013.
Singh M, Alavi A, Wong R, Akita S. Radiodermatitis: a review of our current understanding. Am J Clin Dermatol. 2016;17(3):277-292.
Hammer C, Maduro JH, Bantema-Joppe EJ, et al. Radiation-induced fibrosis in the boost area after three-dimensional conformal radiotherapy with a simultaneous integrated boost technique for early-stage breast cancer: a multivariable prediction model. Radiother Oncol. 2017;122(1):45-49.
Straub JM, New J, Hamilton CD, Lominska C, Shnayder Y, Thomas SM. Radiation-induced fibrosis: mechanisms and implications for therapy. J Cancer Res Clin Oncol. 2015;141(11):1985-1994.
Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and reliability of the US National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol. 2015;1(8):1051-1059.
Allali S, Carton M, Sarrade T, et al. CANTO-RT: skin toxicities evaluation of a multicentre large prospective cohort of irradiated patients for early-stage breast cancer. Int J Cancer. 2022;151:1098-1108.
Yoshida EJ, Chen H, Torres MA, Curran WJ, Liu T. Spectrophotometer and ultrasound evaluation of late toxicity following breast-cancer radiotherapy. Med Phys. 2011;38(10):5747-5755.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341-1346.
Bazire L, Fromantin I, Diallo A, et al. Hydrosorb® versus control (water based spray) in the management of radio-induced skin toxicity: results of multicentre controlled randomized trial. Radiother Oncol. 2015;117(2):229-233.
Kirova YM, Fromantin I, De Rycke Y, et al. Can we decrease the skin reaction in breast cancer patients using hyaluronic acid during radiation therapy? Results of phase III randomised trial. Radiother Oncol. 2011;100(2):205-209.
Silvestri M, Cristaudo A, Morrone A, et al. Emerging skin toxicities in patients with breast cancer treated with new cyclin-dependent kinase 4/6 inhibitors: a systematic review. Drug Saf. 2021;44(7):725-732.
Bhardwaj M, Chiu MN, Pilkhwal SS. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance. Cutan Ocul Toxicol. 2022;41(1):73-90.
Anoop TM, Joseph PR, Pn M, Kp P, Gopan G, Chacko S. Cutaneous toxicities in breast cancer patients receiving chemotherapy and targeted agents: an observational clinical study. Clin Breast Cancer. 2021;21(4):e434-e447.
Brouwers PJAM, van Werkhoven E, Bartelink H, et al. Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: results of the young boost trial. Radiother Oncol. 2018;128(3):434-441.
De Santis MC, Bonfantini F, Di Salvo F, et al. Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy. Breast. 2016;29:90-95.
Kuptsova N, Chang-Claude J, Kropp S, et al. Genetic predictors of long-term toxicities after radiation therapy for breast cancer. Int J Cancer. 2008;122(6):1333-1339.
Ghannam Y, Di Meglio A, Sarrade T, et al. Impact of radiation therapy on fatigue at 1 year in breast cancer survivors in the prospective multicentre CANcer TOxicity cohort. Eur J Cancer. 2022;177:143-153.
Sarrade T, Allodji R, Ghannam Y, et al. CANTO-RT: one of the largest prospective multicenter cohort of early breast cancer patients treated with radiotherapy including full DICOM RT data. Cancers (Basel). 2023;15(3):751.
Vaz-Luis I, Cottu P, Mesleard C, et al. UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO). ESMO Open. 2019;4(5):e000562.
R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Core Team; 2013.
Cao KI, Salviat F, Laki F, et al. Outcomes of postoperative radiation therapy for breast cancer in older women according to age and comorbidity status: an observational retrospective study in 752 patients. J Geriatr Oncol. 2018;9(6):600-605.
Poi MJ, Berger M, Lustberg M, et al. Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Support Care Cancer. 2013;21(10):2679-2686.
Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663-1671.
Sibaud V, Lebœuf NR, Roche H, et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol. 2016;26(5):427-443.
Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016;28(4):254-263.
Raschi E, Fusaroli M, La Placa M, et al. Skin toxicities with cyclin-dependent kinase 4/6 inhibitors in breast cancer: signals from disproportionality analysis of the FDA adverse event reporting system. Am J Clin Dermatol. 2022;23(2):247-255.
Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810-821.
Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-148.
Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19(3):345-361.
Allali S, Kirova Y. Radiodermatitis and fibrosis in the context of breast radiation therapy: a critical review. Cancers. 2021;13(23):5928.
Lou Y, Wang Q, Zheng J, et al. Possible pathways of capecitabine-induced hand-foot syndrome. Chem Res Toxicol. 2016;29(10):1591-1601.
Lazzari G, Buono G, Zannino B, Silvano G. Breast cancer adjuvant radiotherapy in BRCA1/2, TP53, ATM genes mutations: are there solved issues? Breast Cancer. 2021;13:299-310.
Shanley S, McReynolds K, Ardern-Jones A, et al. Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin Cancer Res. 2006;12(23):7025-7032.
González Sanchis A, Brualla González L, Sánchez Carazo JL, et al. Evaluation of acute skin toxicity in breast radiotherapy with a new quantitative approach. Radiother Oncol. 2017;122(1):54-59.
Landoni V, Giordano C, Marsella A, et al. Evidence from a breast cancer hypofractionated schedule: late skin toxicity assessed by ultrasound. J Exp Clin Cancer Res. 2013;32:80.
Kelemen G, Varga Z, Lázár G, Thurzó L, Kahán Z. Cosmetic outcome 1-5 years after breast conservative surgery, irradiation and systemic therapy. Pathol Oncol Res. 2012;18(2):421-427.
Doré M, Hennequin C. Late sequelae and cosmetic outcome after radiotherapy in breast conserving therapy. Cancer Radiother. 2012;16(5-6):462-469.